Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
47 hedge funds and large institutions have $64M invested in Genocea Biosciences, Inc. in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 11 reducing their positions, and 6 closing their positions.
517% more call options, than puts
Call options by funds: $37K | Put options by funds: $6K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
18% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 11
2% less funds holding
Funds holding: 48 → 47 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
19% less capital invested
Capital invested by funds: $79.4M → $64M (-$15.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$358K |
| 2 |
AA
AlphaMark Advisors
Ft. Wright,
Kentucky
|
+$321K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$165K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$138K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$79.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
Ellington Management Group
Old Greenwich,
Connecticut
|
-$200K |
| 2 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
-$175K |
| 3 |
Franklin Resources
San Mateo,
California
|
-$128K |
| 4 |
Millennium Management
New York
|
-$120K |
| 5 |
Goldman Sachs
New York
|
-$94.8K |
GNCA Hedge Fund Activity: Q4 2016 in Review
47 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q4 2016, worth a combined $64M — down 19% from $79.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of GNCA and 5 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 13 added.
The largest buyer was Sphera Funds Management, adding an estimated $358K. The largest seller was Ellington Management Group, exiting entirely with an estimated $200K sold.
- 47 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q4 2016, down from 48 in Q3 2016.
- Funds reported $64M of Genocea Biosciences, Inc. stock for Q4 2016, down 19% quarter-over-quarter.
- 5 funds opened new Genocea Biosciences, Inc. positions in Q4 2016 and 6 closed out, a net change of -1 holder.
- The largest Genocea Biosciences, Inc. buyer in Q4 2016 was Sphera Funds Management, an estimated $358K added.
- The largest Genocea Biosciences, Inc. seller in Q4 2016 was Ellington Management Group, an estimated $200K sold.
Based on aggregated 13F filings for Q4 2016.